I do think a swift process is possible.
1. Commercial manufacturing facility inspection/approval/granted fresh from March 2023.
2. HTA inspection/approval/renewal/granted concurrent with submission/validation of maa.
3. All electronic databases double checked prior to submission.
4. Final section of MAA edited by two different editors.
5. MHRA “swift approval process” announced by Jeremy Hunt in March 2023 for “high impact” therapies like ”cancer vaccines”, was located just two business days ahead of Advent’s (most advanced UK cell manufacturing facility) announcement of commercial license for its facility. It doesn’t take a genius to surmise the actual pass may have been concurrent
Anyway, my gut tells me the double editing, concurrent HTA/MAA actions, concurrent MHRA announcement/actions are somehow more than just a coincidence.